Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study.

The Lancet Infectious Diseases
David van DuinMulti-Drug Resistant Organism Network Investigators

Abstract

Carbapenem-resistant Enterobacterales (CRE) are a global threat. We aimed to describe the clinical and molecular characteristics of Centers for Disease Control and Prevention (CDC)-defined CRE in the USA. CRACKLE-2 is a prospective, multicentre, cohort study. Patients hospitalised in 49 US hospitals, with clinical cultures positive for CDC-defined CRE between April 30, 2016, and Aug 31, 2017, were included. There was no age exclusion. The primary outcome was desirability of outcome ranking (DOOR) at 30 days after index culture. Clinical data and bacteria were collected, and whole genome sequencing was done. This trial is registered with ClinicalTrials.gov, number NCT03646227. 1040 patients with unique isolates were included, 449 (43%) with infection and 591 (57%) with colonisation. The CDC-defined CRE admission rate was 57 per 100 000 admissions (95% CI 45-71). Three subsets of CDC-defined CRE were identified: carbapenemase-producing Enterobacterales (618 [59%] of 1040), non-carbapenemase-producing Enterobacterales (194 [19%]), and unconfirmed CRE (228 [22%]; initially reported as CRE, but susceptible to carbapenems in two central laboratories). Klebsiella pneumoniae carbapenemase-producing clonal group 258 K pneumoniae was the...Continue Reading

Associated Clinical Trials

Citations

Apr 9, 2020·Pharmacotherapy·Thomas P Lodise, Michael J Rybak
Apr 3, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jason C Gallagher
Apr 7, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Majdi N Al-Hasan
Sep 30, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ahmed BabikerRyan K Shields
Dec 31, 2020·Antibiotics·José Francisco García-RodríguezAna Mariño-Callejo
Jan 28, 2021·Infection and Drug Resistance·Xing TanZackery P Bulman
Mar 26, 2021·Transactions of the Royal Society of Tropical Medicine and Hygiene·Jaffar A Al-TawfiqAli M Bazzi
Mar 26, 2021·Frontiers in Microbiology·Yanqin HuangZackery P Bulman
May 26, 2021·Expert Review of Anti-infective Therapy·Ilias KaraiskosHelen Giamarellou
May 26, 2021·Antimicrobial Agents and Chemotherapy·Erin K McCrearyPranita D Tamma
Jun 26, 2021·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Kathleen Tompkins, David van Duin
Jul 2, 2021·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·Marco FalconeUNKNOWN Italian Group of Antimicrobial Stewardship (the GISA study group)
Aug 8, 2021·Infectious Disease Clinics of North America·Geeta Sood, Trish M Perl
May 11, 2021·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·M Hong NguyenCornelius J Clancy
Jul 7, 2021·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Aurora Páez-VegaJulián Torre-Cisneros
Aug 28, 2021·Journal of Pharmacy Practice·Taryn A EubankUNKNOWN Houston Infectious Diseases Network
Aug 3, 2021·Antimicrobial Agents and Chemotherapy·Blake M HansonBhavarth S Shukla
Oct 8, 2021·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Vance G FowlerKathy Talkington

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Related Papers

The Lancet Infectious Diseases
Sumanth Gandra, Carey-Ann D Burnham
Current Infectious Disease Reports
Kathleen ChiotosPranita D Tamma
© 2021 Meta ULC. All rights reserved